Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
ACS CAN
Apr 21, 2024, 21:27 |
Drugs
Hagop Kantarjian: We review the evidence leading to Tagraxofusp approval as first in class CD123-directed drug which has changed the field of BPDCN
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: “Tazgraxofusp is…
Apr 20, 2024, 08:50 |
Blog
Cristiane Bergerot: It's time to integrate evidence-based FCR interventions into existing guidelines to enhance survivorship and alleviate silent suffering
Cristiane Bergerot shared on X/Twitter: "Proud to have collaborated on this document with star colleagues. Daniel…
Apr 18, 2024, 17:18 |
Career
Hannah Wallace: Call for ambassadors, join the movement
Hannah Wallace, Director of Development at American Cancer Society, shared on LinkedIn: “Call for ambassadors: Join…
Apr 13, 2024, 03:43 |
Blog
FDA ODAC voted 12-0. Historic victory in multiple myeloma
On April 12, 2024, FDA ODAC voted 12-0 in favor of using minimal residual disease…
Apr 12, 2024, 11:25 |
Insight
A Paper in Nature Genetics identifies 41 cell subtypes and highlights age and parity-dependent effects in analysis of over 800.000 human adult breast cells - Nature Portfolio
Apr 7, 2024, 23:19 |
Blog
Arif Kamal: 31 is a unique number
Arif Kamal, Chief Patient Officer at the American Cancer Society, posted on LinkedIn: “31 is a…
Apr 7, 2024, 11:45 |
Drugs
Yüksel Ürün: Adding immunotherapy to cabozantinib for mccRCC after 1st line immunotherapy showed no extra benefit in real-world data
Yüksel Ürün, Doctorate Professor at the Faculty of Medicine, Ankara University, Turkey, shared a post…
Apr 7, 2024, 07:08 |
Insight
Wafik El-Deiry: Clinical development portfolio at AACR24 by Michael Pourdehnad
Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University, recently posted on LinkedIn:…
Apr 4, 2024, 20:02 |
Drugs
Georges Gebrael: RWD of Cabozantinib and ICI vs. cabozantinib monotherapy align with CONTACT03 trial results
Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah, shared on X/Twitter:…
Apr 4, 2024, 14:05 |
Insight
Toni Choueiri: More evidence that ICI after ICI may not be effective
Toni Choueiri, Professor of Medicine at Harvard Medical School and Director of the Lank Center…
50
51
52
53
54
All:
557
Posts:
511 - 520
Top 100 Xfluencers in Pediatric Hematology/Oncology: Key Opinion Leaders to follow on X (Twitter) in 2024
Jeff Bridges and Lymphoma: How He Went Against, How He Survived, and More
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 5
Familial Adenomatous Polyposis: Alarming Symptoms, Causes, Types, Diagnosis and Treatment
OncoDaily Party Barcelona
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube